Abstract:Tau has a wide variety of essential functions in the brain, but this protein also plays a determining role in the development of Alzheimer's disease (AD) and other neurodegenerative diseases called tauopathies. This is due to its abnormal aggregation and the subsequent formation of neurofibrillary tangles. Tau hyperphosphorylation appears to be a critical step in its transformation into an aggregated protein. However, the exact process, including the cellular events that trigger it, remains unclear. In this study, we employed immunocytochemistry assays on hippocampal sections from AD cases and from tauopathy cases (Braak stage III) with no evidence of cognitive decline, and the P301S mouse model to investigate the colocalization patterns of Tau phosphorylated (p) at specific residues (S202-T205, S214, and T231) within the proline-rich region. Our results show pyramidal neurons in the hippocampus of P301S mice in which Tau is intensely phosphorylated at residues S202 and T205 (recognized by the AT8 antibody), but with no detectable phosphorylation at S214 or T231. These non-colocalizing neurons displayed intensely labeled aggregated pTau deposits distributed through the soma and dendritic processes. However, most of the hippocampal pyramidal neurons are labeled with pTauS214 or pTauT231 antibodies and typically showed a homogeneous and diffuse pTau distribution (not aggregated). This different labeling likely reflects a Tau conformational step, potentially related to the transition from a diffuse tau phosphorylation phenotype (Type 2) into an NFT-like or Type 1 phenotype. We further observed that dendrites of CA3 pyramidal cells are intensely labeled with pTau214 in the stratum lucidum, but not with AT8 or pTauT231. By contrast, analysis of tissue from AD patients or other human tauopathy cases (Braak stage III) with no evidence of cognitive decline revealed extensive colocalization with both antibody combinations in CA1. The complete or mature tangle development may follow a different mechanism in the P301S mouse model or may require more time to achieve the maturity state found in AD cases. Further studies would be necessary to address this question.

Alzheimer’s Disease and Tau Self-Assembly: In the Search of the Missing Link

The Self-Assembly Ability of the First Microtubule-Binding Repeat from Tau and Its Modulation by Phosphorylation

F2-06-01: MAJOR DIFFERENCES BETWEEN THE SELF-ASSEMBLY, SEEDING BEHAVIOR, AND INTERACTION WITH MODULATORS OF HEPARIN-INDUCED VERSUS IN-VITRO PHOSPHORYLATED TAU

Alzheimer's Disease Seeded Tau Forms Paired Helical Filaments Yet Lacks Seeding Potential

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Evaluating Triggers and Enhancers of Tau Fibrillization

Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies

Phosphorylation and O-GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates

Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease

Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology

Targeting Abnormal Tau Phosphorylation for Alzheimer's Therapeutics

Role of Microtubule-Associated Protein Tau Phosphorylation in Alzheimer’s Disease

Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent inflammatory responses

Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses

Complicated Role of Post-translational Modification and Protease-Cleaved Fragments of Tau in Alzheimer’s Disease and Other Tauopathies

Distinct Microscopic Mechanisms for the Accelerated Aggregation of Pathogenic Tau Mutants Revealed by Kinetic Analysis.

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

Tau Acts in Concert With Kinase/Phosphatase Underlying Synaptic Dysfunction

Tau Ubiquitination in Alzheimer's Disease

Mechanistic Insights and Future Challenges